DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.
BD's (BDX) New FDA Approval to Improve MRSA Diagnostics
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve laboratory workflow.
Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays
by Zacks Equity Research
Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.
LabCorp (LH) Expands Laboratory Relationship With New Pact
by Zacks Equity Research
LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.
NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.
3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets
by Zacks Equity Research
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.
Here's Why You Should Hold Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and well-performing Medicaid and Medicare segments poise it for growth.
Earnings Estimates Rising for DaVita HealthCare (DVA): Will It Gain?
by Zacks Equity Research
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
2 Top-Rated Medical Stocks to Buy After Earnings
by Shaun Pruitt
As we round out this week's earnings lineup, a few healthcare companies are standing out after topping their quarterly earnings expectations.
Is Addus HomeCare (ADUS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DaVita HealthCare (DVA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View
by Zacks Equity Research
DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 46.30% and 1.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Misses Q1 Earnings Estimates
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -13.33% and 3.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
U.S. Physical Therapy (USPH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 13.46% and 6.19%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
DaVita (DVA) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite DaVita's (DVA) robust revenues in its Other segment, its overall Q4 performance was soft.
DaVita HealthCare (DVA) Q4 Earnings Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 26.14% and 0.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More
by Debanjana Dey
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Addus HomeCare (ADUS) Reports Next Week: What to Expect
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.